NCT06860542View on ClinicalTrials.gov

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2030

Conditions
PneumonitisImmune-related Adverse Event
Interventions
DRUG

Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care

Budesonide (Pulmicort® Turbuhaler®) 800ug inhaled twice daily (BID) will be taken in addition to usual care for 36 weeks.

OTHER

Arm 1- Usual care

The comparison arm will be usual care (UC) for Checkpoint inhibitor pneumonitis (CIP) (steroids).

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER